Study Design
SEVERE OBESITY
The BARIVA study was designed as an investigator-initiated, assessor-blinded, multicenter, phase 2 randomized clinical trial with a calculated number of 130 patients in each of the 2 study groups: short vs long prophylaxis with rivaroxaban in patients with severe obesity after bariatric surgery. The study was conducted at 3 bariatric centers in Switzerland from July 1, 2018, to June 30, 2021. All patients provided written informed consent. The trial was performed according to the Declaration of Helsinki,